Introduction
============

The elimination of anesthetic agents, especially from the brain, is a decisive factor in the emergence from general anesthesia. Rapid elimination of anesthetic agents from the brain enables faster emergence. In case of volatile anesthetics, many studies have reported on the effect of hyperventilation and hypercapnia \[[@b1-kja-d-18-27068]--[@b5-kja-d-18-27068]\].

Propofol has gained wide acceptance among anesthesiologists due to its favorable induction characteristics, including its rapid onset time and fast elimination half-life \[[@b6-kja-d-18-27068]\]. Rapid elimination of propofol from the blood and brain may be expected to shorten the emergence time. Hypercapnia increases cardiac output (CO) and cerebral blood flow (CBF) \[[@b2-kja-d-18-27068]\]. Previous studies have shown that increased CO following administration of dopamine, norepinephrine, epinephrine, or ephedrine during the maintenance phase of anesthesia is related to a lower blood concentration of propofol and higher bispectral index (BIS) values \[[@b7-kja-d-18-27068]--[@b11-kja-d-18-27068]\]. Therefore, hypercapnia could promote propofol elimination from the blood and the brain and, in turn, shorten the emergence time.

We carried out this pilot study because only a few clinical studies have investigated the relationship between hypercapnia and emergence time with propofol anesthesia. We aimed to assess study feasibility and treatment effect of hypercarbia on emergence time from propofol anesthesia; in addition, we intended to estimate a sample size required for the main study. We hypothesized that the emergence time from propofol anesthesia in patients with hypercapnia would be different from those with hypocapnia. We aimed to compare time to eye opening, time to mouth opening, and time to tracheal extubation in patients with hypo- and hypercapnia and assess outcomes.

Materials and Methods
=====================

After approval from the Institutional Review Board, adult patients aged 20--60 years, with American Society of Anesthesiology physical status 1 to 2, were informed of the method and purpose of this prospective, randomized, and controlled clinical pilot research. Written consent was obtained from all participants. There were 42 participants, 26 men and 16 women. We excluded patients with psychiatric, pulmonary, cardiac, endocrinal, neuromuscular, hepatic, and neurological diseases or with a history suggestive of such illnesses. Smokers, patients on regular sedatives or other medication likely to affect the study, those who had been under general anesthesia within the past month or had a body mass index of 30 kg/m^2^ or more were also excluded. All patients underwent elective orthopedic surgery of the hand or elbow under general anesthesia lasting from 1 to 3 h from January 2012 to June 2013. The protocol for this study has been registered with Clinicaltrials.gov, and the registration number is NCT01531491.

A random allocation sequence was generated with Microsoft Excel 2010. Allocation into groups was made by opening opaque sealed envelopes. Patients were randomly divided into two groups based on end-tidal carbon dioxide (ETCO~2~) levels: 30 mmHg (the hypocapnia group) or 50 mmHg (the hypercapnia group) immediately prior to emergence from propofol anesthesia. Patients were blinded to the group allocation. To blind the physician who provided anesthetic care to the groups, ETCO~2~ was monitored with a separate monitoring device (SAM module, Solar8000M, GE Healthcare, USA). A blinded third investigator recorded the data during emergence. Patients and the data analyst were also not aware of the treatment allocation.

No premedication was administrated. In the operating room, routine monitoring was commenced, including non-invasive blood pressure, electrocardiogram, pulse oximetry and BIS sensors. After pre-oxygenation with 100% oxygen with a fresh gas flow of 6 L/min, anesthesia was induced with propofol 2 mg/kg, remifentanil 1 μg/kg, and a non-depolarizing neuromuscular blocking agent. Intubation was carried out with 7.5 mm ID (internal diameter) tubes in men and 7.0 mm ID tubes in women. During the maintenance phase, a fresh gas flow of 2 L/min with fractional inspired oxygen concentration of 0.4 and propofol infusion at 120 μg/kg/min were administered. Remifentanil was infused at a dose of 0.1 to 0.25 μg/kg/min to maintain a BIS value of 40--50. Patients in whom the BIS values could not be maintained within this range with remifentanil infusion were excluded from the study. The respiratory rate was set at 10 breaths/min, and the tidal volume was controlled to maintain ETCO~2~ at 30 mmHg during surgery.

Remifentanil infusion was discontinued 10 min prior to discontinuation of propofol. Following this, 0.4 mg of glycopyrrolate and 15 mg of pyridostigmine were administered, and a train-of-four ratio equal to or greater than 0.9 was confirmed. The fresh gas flow was increased to 6 L/min with 100% oxygen. Emergence began when the administration of propofol was discontinued. The propofol infusion line was connected directly to the intravenous catheter using a three-way stopcock.

During emergence, no modifications were made to the ventilation settings in the hypocapnia group. In the hypercapnia group, a rebreathing tube (about 750 ml) was connected between the corrugated tube and the endotracheal tube to achieve an ETCO~2~ of 50 mmHg ([Fig. 1](#f1-kja-d-18-27068){ref-type="fig"}).

The time at which the patient started coughing or the ETCO~2~ level began to change on the capnography was considered as the 'time to spontaneous respiration' and recorded. Patients were asked to open the eyes every 30 s after the discontinuation of propofol. The time to eye opening was recorded; following this, they were asked to open the mouth, and the time was recorded as time to mouth opening. When spontaneous respiratory efforts were adequate, extubation was carried out (time to tracheal extubation), and then the patient was transfered to the post-anesthesia care unit. At every step of emergence, the time taken from the discontinuation of propofol to appropriate patient responses was recorded. ETCO~2~ values and BIS scores were recorded at the time of eye opening and tracheal extubation. Pre-emergence BIS values were recorded at the time of discontinuation of propofol.

Being a pilot study, we did not estimate sample size. The primary endpoint was time to eye opening after discontinuation of propofol. We expected to detect a difference in mean time to eye opening of 5 min \[[@b4-kja-d-18-27068]\]. Secondary endpoints were time to spontaneous respiration, time to mouth opening, and time to tracheal extubation. Differences in emergence pattern between males and females between the two groups were compared using the Fisher's exact test. According to the results of the Shapiro-Wilk test for the normality test, age, height, weight, body temperature, hemoglobin, anesthetic time, time to eye opening, time to spontaneous respiration, time to mouth opening, and time to tracheal extubation were compared using a student's t-test. Pre-emergence BIS and the total dose of remifentanil and propofol infused were compared using the Mann-Whitney U test.

The time to eye opening was analyzed with a multiple linear regression using sex, age, anesthesia time, and initial BIS as variables. Backward stepwise variable selection was applied. We used a scatter plot to check the linearity between the independent and dependent variables, a QQ plot for normality, Durbin-Watson test for independency. Homoscedasticity was checked using a scatter plot. Collinearity of the explanatory variables was also evaluated with variable inflation factors. Data were presented as mean (95% CI) or median (1Q, 3Q). A P value \< 0.05 indicated statistical significance. All statistical calculations were made using SAS (version 9.3, SAS Institute Inc., USA).

Results
=======

Thirty out of 42 patients completed the study ([Fig. 2](#f2-kja-d-18-27068){ref-type="fig"}). No significant difference was observed between groups, in demographic characteristics and the duration of anesthesia. The total dose of remifentanil and propofol administered was similar ([Table 1](#t1-kja-d-18-27068){ref-type="table"}). The median (1Q, 3Q) ETCO~2~ level was 31 (29, 32) mmHg in the hypocapnia group and 51 (49, 52) mmHg in the hypercapnia group at the time of eye opening (P \< 0.001).

The mean time to eye opening was 9.7 min in the hypocapnia group and 9.0 min in the hypercapnia groups (P = 0.688) without any difference between them (−0.7 min, 95% CI, −4.0 to 2.7 min; P = 0.645).

There was no statistically significant difference in secondary outcomes such as time to spontaneous respiration (P = 0.645), time to mouth opening (P = 0.576), and time to tracheal extubation (P = 0.447) ([Table 2](#t2-kja-d-18-27068){ref-type="table"}).

Sex and pre-emergence BIS were found to be associated with emergence on multiple regression analysis. Females recovered about 3.6 min (95% CI, −6.1 to −1.1; P = 0.009) faster than males. Higher initial BIS was related to an earlier recovery from the propofol anesthesia (2.2 min; 95% CI, −3.2 to −1.2 min; P \< 0.001) ([Table 3](#t3-kja-d-18-27068){ref-type="table"}). It means that if the initial BIS is 10 points higher at the end of propofol anesthesia, eye opening would occur 2.2 min earlier. The explanatory power (r^2^) of this regression model was 48.5%.

Discussion
==========

In this study, we hypothesized that hypercapnia, by increasing CO and CBF, would shorten emergence time from propofol anesthesia. Time to eye opening was 9.7 (1.3) min in the hypocapnia group and 9.0 (1.0) min in the hypercapnia group. Additionally, on multiple regression analysis, a statistically significant difference was observed between males and females in times to eye opening.

We conceptualized a difference in the mean time to eye opening of 5 min, which we deemed to be clinically significant \[[@b4-kja-d-18-27068]\]. However, the difference was only −0.7 min (95% CI, −4.0 to 2.7), which was neither statistically nor clinically significant (P = 0.688). Therefore, the study methodology needs to be modified to augment the effect of hypercapnia on emergence time. Hypercapnia induced at the time of discontinuation of propofol infusion, combined with earlier cessation of remifentanil infusion and/or administration of catecholamine infusions, may be considered.

We recruited 42 patients who were eligible for the study; 15 patients completed the study in each group. However, we found that the sample size (n = 15) we estimated was adequate for a full study. The sample size was estimated based on a difference in mean times to eye opening of 5 min, with two standard deviations of 3.8 and 5.0 min and power of 0.8 at a two-tailed significance level of 0.05. Hence, we concluded that further study regarding the effect of hypercapnia on emergence time with a larger sample size may not be required.

Propofol is rapidly metabolized in the liver, but its clearance exceeds the hepatic blood flow and extrahepatic metabolism has been suggested to occur. The kidneys play an important role in elimination, accounting for up to 30% of the extrahepatic metabolism \[[@b12-kja-d-18-27068],[@b13-kja-d-18-27068]\]. Propofol is also eliminated by the lungs, resulting in a 20--30% decrease in the blood levels \[[@b14-kja-d-18-27068],[@b15-kja-d-18-27068]\]. Thus, an increase in CO may decrease the serum concentration of propofol by increasing the blood flow to organs that eliminate the drug.

Hypercapnia increases CBF, and therefore, it may accelerate the rate of propofol clearance from the brain, similar to volatile anesthetics \[[@b1-kja-d-18-27068],[@b16-kja-d-18-27068]\]. An increase in CO due to hypercapnia decreases the propofol concentration in the blood while increasing the cerebral capillary/tissue diffusion gradient. Therefore, hypercapnia may be important in the rapid clearance of propofol from the brain. Hypercapnia initially causes a decrease in CO and an increase in CBF. However, by increasing venous return, eventually the overall effect of hypercapnia is an increase in CO and CBF with propofol anesthesia \[[@b11-kja-d-18-27068],[@b17-kja-d-18-27068]--[@b19-kja-d-18-27068]\]. Without any modification of the ventilation settings, hypercapnia was achieved by connecting a rebreathing tube, because propofol is not exhaled through the lungs, unlike volatile anesthetics.

A more rapid emergence time in females has also been shown in previous studies \[[@b20-kja-d-18-27068],[@b21-kja-d-18-27068]\]. It is speculated that females have a lower sensitivity to propofol or are capable of metabolizing propofol more rapidly than males. Choong et al. \[[@b22-kja-d-18-27068]\] reported that propofol was metabolized by UDP-glucuronosyltranferase 1A9 and cytochrome P-450 enzyme 2B6. Although sex is regarded as an unrelated factor to the gene expression of these enzymes, women have faster metabolic rates of these enzymes than men \[[@b22-kja-d-18-27068]\]. It is reasonable to assume that the influences of sex on the mean time of eye opening would be significant statistically, but not clinically, because the difference was only 3.6 min. However, since the lower limit of the 95% CI was −6.1 min, we could assume that the influences of sex on the mean time to eye opening may be plausible.

Although higher initial BIS values were related to an earlier recovery from the propofol anesthesia, it is reasonable to assume that an increase by 10 points may not be clinically significant because the 95% CI did not show a difference of 5 min in the mean times to eye opening.

This pilot study has several limitations. First, pre-induced hypercapnia before the discontinuation of propofol would enable a further increase in CO and CBF during recovery, which may meaningfully shorten the emergence time. Measuring CO and CBF would also be helpful to understand the relationship between the hypercapnia and emergence time. Second, we stopped the remifentanil infusion 10 min before discontinuing propofol. Even though remifentanil is eliminated rapidly from the blood, this may still have influenced the time to recovery. Third, assuming that there may be sex differences in the metabolism of propofol, further studies are required to address this possibility. Lastly, we did not measure the plasma concentration of propofol in this study because CO itself changes the blood propofol concentration, and we assumed that hypercapnia could shorten the emergence time. However, for more accurate results, blood propofol concentration needs to be measured in future studies.

In conclusion, in this pilot study, we could not detect a beneficial effect of hypercapnia on emergence times during recovery from propofol anesthesia. In addition, irrespective of hypercapnia, females tend to recover faster than males.

![Rebreathing device. The distal part of the rebreathing tube was connected to the patient and the proximal part was connected to a Y-type connector of the corrugated tube. The diameter of rebreathing tube was 1 cm and the length was 12−15 cm.](kja-d-18-27068f1){#f1-kja-d-18-27068}
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###### 

Patients' Characteristics

  Variable                                                                          Hypocapnia group (n = 15)   Hypercapnia group (n = 15)   P value
  --------------------------------------------------------------------------------- --------------------------- ---------------------------- ---------
  Sex (M/F)^[\*](#tfn1-kja-d-18-27068){ref-type="table-fn"}^                        10/5                        11/4                         1.000
  Age (yr)                                                                          37 (8)                      41 (9)                       0.165
  Height (cm)                                                                       169 (10)                    166 (9)                      0.368
  Weight (kg)                                                                       66.9 (14.0)                 66.3 (12.4)                  0.902
  Body temperature (°C)                                                             36.4 (0.4)                  36.6 (0.3)                   0.123
  Hb (g/dl)                                                                         14.1 (3.6)                  14.4 (3.2)                   0.632
  Anesthetic time (min)                                                             99 (36)                     107 (38)                     0.557
  Pre-emergence BIS^[†](#tfn2-kja-d-18-27068){ref-type="table-fn"}^                 46 (39, 53)                 43 (36, 48)                  0.457
  Total infused remifentanil (μg)^[†](#tfn2-kja-d-18-27068){ref-type="table-fn"}^   1250 (1000, 1250)           1250 (1000, 1275)            0.447
  Total infused propofol (mg)^[†](#tfn2-kja-d-18-27068){ref-type="table-fn"}^       1000 (770, 1100)            960 (750, 1140)              0.913

Values are expressed as mean (SD), median (1Q, 3Q), or number of patients. Hypocapnia: End-tidal carbon dioxide of 30 mmHg, Hypercapnia: End-tidal carbon dioxide of 50 mmHg, Pre-emergence BIS: Initial bispectral index value at the discontinuation of propofol.

Fisher's exact test,

Mann-Whitney U test.

###### 

Mean Time of Emergence Events and Difference between the Hypocapnia and Hypercapnia Groups

  Emergence events          Hypocapnia group (n = 15)   Hypercapnia group (n = 15)   Difference (95% CI)   P value
  ------------------------- --------------------------- ---------------------------- --------------------- ---------
  Spontaneous respiration   8.6 (1.2)                   7.9 (1.0)                    −0.7 (−4.0 to 2.5)    0.645
  Eyes opening              9.7 (1.3)                   9.0 (1.0)                    −0.7 (−4.0 to 2.7)    0.688
  Mouth opening             10.3 (1.3)                  9.4 (1.0)                    −0.9 (−4.4 to 2.5)    0.576
  Tracheal extubation       11.5 (1.3)                  10.3 (0.9)                   −1.2 (−4.5 to 2.0)    0.447

Values (min) are expressed as mean (SE). Hypocapnia: End-tidal carbon dioxide of 30 mmHg, Hypercapnia: End-tidal carbon dioxide of 50 mmHg.

###### 

Independent Predictors of Time to Eyes Opening

  Variable (n = 30)                 Estimate (min)   SE    95% CI         P value
  --------------------------------- ---------------- ----- -------------- ----------
  Sex of female                     −3.6             1.3   −6.1 to −1.1   0.009
  Pre-emergence BIS per 10 points   −2.2             0.5   −3.2 to −1.2   \< 0.001

Pre-emergence BIS: Bispectral index at the discontinuation of propofol, SE: standard error of the estimate. Multiple linear regression analysis was conducted.
